Citalopram, QTc interval prolongation, and torsade de pointes. How should we apply the recent FDA ruling?

American Journal of Medicine

Volumn 125, Issue 9, 2012, Pages 859-868

  Vieweg, W Victor R ^a,b   Hasnain, Mehrul ^c   Howland, Robert H ^d   Hettema, John M ^a,e   Kogut, Christopher ^a   Wood, Mark A ^b   Pandurangi, Ananda K ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^c MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Citalopram; Drug induced QTc interval prolongation; Risk factors; Torsade de pointes

Indexed keywords

CIMETIDINE; CITALOPRAM;

ANXIETY DISORDER; BRADYCARDIA; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; DRUG DOSE ESCALATION; DRUG MARKETING; DRUG MEGADOSE; ELECTROCARDIOGRAPHY; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; INFORMED CONSENT; MEDLINE; PHYSICIAN; PRESCRIPTION; PRIORITY JOURNAL; PUBLISHING; QT PROLONGATION; REVIEW; RISK FACTOR; SIDE EFFECT; SUDDEN DEATH; TORSADE DES POINTES;

ADULT; AGED; AGED, 80 AND OVER; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; DEATH, SUDDEN, CARDIAC; DRUG AND NARCOTIC CONTROL; FEMALE; HEART VENTRICLES; HUMANS; LONG QT SYNDROME; MALE; MIDDLE AGED; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS; TORSADES DE POINTES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84865701003     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2011.12.002     Document Type: Review

References (43)

1. Forest Laboratories CELEXA (citalopram hydrobromide) causes dose dependent QT prolongation (2011) http://www.frx.com/pdf/ DearDrCelexa%20HCP%20Letter%2008-12-2011.pdf Accessed February 12, 2012
2. US Food and Drug Administration FDA Drug Safety Communication: Abnormal heart rhythms associated with high doses of Celexa (citalopram hydrobromide) (August 24, 2011) http://www.fda.gov/Drugs/DrugSafety/ucm269086.htm Accessed February 12, 2012.
3. B. Darpo The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidance Br J Pharmacol 159 2010 49 57
4. S. Berfield A CEO and his son. The remarkable saga of Howard Solomon, his son Andrew, and his company, Forest Labs... a journey of depression and hope BusinessWeek May 27, 2002
5. Food and Drug Administration FDA approves Viibryd to treat major depressive disorder (2011) www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ ucm240642.htm Accessed February 12, 2012.
6. S.L. Rasmussen, K.F. Overo, P. Tanghoj Cardiac safety of citalopram: prospective trials and retrospective analyses J Clin Psychopharmacol 19 1999 407 415
7. A. Jimmink, K. Caminada, N.G. Hunfeld, D.J. Touw Clinical toxicology of citalopram after acute intoxication with the sole drug or in combination with other drugs: overview of 26 cases Ther Drug Monit 30 2008 365 371
8. C. Åström-Lilja, J.M. Odeberg, E. Ekman, S. Hägg Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database Pharmacoepidemiol Drug Saf 17 2008 587 592
9. P.J. Kannankeril, K.J. Norris, S. Carter, D.M. Roden Factors affecting the degree of QT prolongation with drug challenge in a large cohort of normal volunteers Heart Rhythm 8 2011 1530 1534
10. C. Ding Predicting the degree of drug-induced QT prolongation and the risk for torsades de pointes Heart Rhythm 8 2011 1535 1536
11. A.J. Camm, M. Malik, Y.G. Yap Acquired Long QT Syndrome 2004 Blackwell Futura London
12. K. Wenzel-Seifert, M. Wittmann, E. Haen Torsade de pointes episodes under treatment with selective serotonin reuptake inhibitors Pharmacopsychiatry 43 2010 279 281
13. National Institute of Mental Health Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Study (2011) http://mentalhealth.gov/trials/ practical/stard/index.shtml Accessed February 12, 2012
14. D. Marazziti, F. Golia, G. Consoli Effectiveness of long-term augmentation with citalopram to clomipramine in treatment-resistant OCD patients CNS Spectr 13 2008 971 976
15. W.V.R. Vieweg, M.A. Wood, A. Fernandez, M. Beatty-Brooks, M. Hasnain, A.K. Pandurangi Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly Drugs Aging 26 2009 997 1012
16. W.V.R. Vieweg, M. Hasnain, M.A. Wood, A. Fernandez, E.J. Lesnefsky, A.K. Pandurangi Cardiometabolic risks of antidepressant and antipsychotic drugs, Part 1 Proarrhythmic risks of antidepressant and antipsychotic drugs Psychiatr Times 28 2011 50 55
17. G. Catalano, M.C. Catalano, M.A. Epstein, P.E. Tsambiras QTc interval prolongation associated with citalopram overdose: a case report and literature review Clin Neuropharmacol 24 2001 158 162
18. K.M. Engebretsen, C.R. Harris, J.E. Wood Cardiotoxicity and late onset seizures with citalopram overdose J Emerg Med 25 2003 163 166
19. H.C. Bazett An analysis of the time-relations of electrocardiograms Heart 7 1920 353 370
20. J.H. Indik, E.C. Pearson, K. Fried, R.L. Woosley Bazett and Fridericia QT correction formulas interfere with measurement of drug-induced changes in QT interval Heart Rhythm 3 2006 1003 1007
21. S. Kanjanauthai, T. Kanluen, P. Chareonthaitawee Citalopram induced torsade de pointes, a rare life threatening side effect Int J Cardiol 131 2008 e33 e34
22. A. Tarabar, R. Hoffman, L. Nelson Citalopram overdose: late presentation of torsades de pointes (TdP) with cardiac arrest J Med Toxicol 4 2008 101 105
23. M. Bruggisser, A. Bravo, M. Bodmer Medication associated long QT syndrome Praxis (Bern 1994) 98 2009 1409 1415
24. A. Tanaka, S. Koga, Y. Hiramatsu Donepezil-induced adverse side effects of cardiac rhythm: 2 cases report of atrioventricular block and Torsade de Pointes Intern Med 48 2009 1219 1223
25. J. Liotier, F. Coudoré Drug monitoring of a case of citalopram overdosage Drug Chem Toxicol 34 2011 420 423
26. A. Fayssoil, J. Issi, M. Guerbaa, J.C. Raynaud, V. Heroguelle Torsade de pointes induced by citalopram and amiodarone Ann Cardiol Angéiol 60 2011 165 168
27. C. de Gregorio, G. Morabito, M. Cerrito, G. Dattilo, G. Oreto Citalopram-induced long QT syndrome and torsade de pointes: role for concomitant therapy and disease Int J Cardiol 148 2011 226 228
28. S. Unterecker, B. Warrings, J. Deckert, B. Pfuhlmann Correlation of QTc interval prolongation and serum level of citalopram after intoxication - a case report Pharmacopsychiatry 45 1 2012 30 34
29. P. Lanjewar, V. Pathak, Y. Lokhandwala Issues in QT interval measurement Indian Pacing Electrophysiol J 4 2004 156 161
30. W.V.R. Vieweg, K.C. Stanton, J.S. Alpert, A.D. Hagan Rate-dependent left bundle branch block with angina pectoris and normal coronary arteriograms Chest 69 1976 123 124
31. S. Talbot QT interval in right and left bundle-branch block Br Heart J 35 1973 288 291
32. G. Das QT interval and repolarization time in patients with intraventricular conduction delay J Electrocardiol 23 1990 49 52
33. L. Calo, M. Levato, L. Sciarra The effects of a left bundle-branch block on ventricular repolarization dispersion Cardiologia 41 1996 1073 1077
34. P.M. Rautaharju, Z.M. Zhang, R. Prineas, G. Heiss Assessment of prolonged QT and JT intervals in ventricular conduction defects Am J Cardiol 93 2004 1017 1021
35. Psychopharmacological Drugs Advisory Committee July 19 Briefing Document for ZELDOX CAPSULES (Ziprasidone HCl) - Pfizer www.fda.gov/ohrms/dockets/ac/00/ backgrd/3619b1a.pdf Accessed February 12, 2012
36. W.V.R. Vieweg, R.K. Schneider, M.A. Wood Torsade de pointes in a patient with complex medical and psychiatric conditions receiving low-dose quetiapine Acta Psychiatr Scand 112 2005 319 323
37. Y. Zhang, W.S. Post, D. Dalal, E. Blasco-Colmenares, G.F. Tomaselli, E. Guallar QT-interval duration and mortality rate: results from the Third National Health and Nutrition Examination Survey Arch Intern Med 171 2011 1727 1733
38. W.A. Ray, S. Meredith, P.B. Thapa, K.G. Meador, K. Hall, K.T. Murray Antipsychotics and the risk of sudden cardiac death Arch Gen Psychiatry 58 2001 1161 1167
39. W.A. Ray, C.P. Chung, K.T. Murray, K. Hall, C.M. Stein Atypical antipsychotic drugs and the risk of sudden cardiac death N Engl J Med 360 2009 225 235
40. D. Warden, A. Rush, M. Trivedi, M. Fava, S. Wisniewski The STAR*D project results: a comprehensive review of findings Curr Psychiatry Rep 9 2007 449 459
41. R.H. Howland A critical evaluation of the cardiac toxicity of citalopram: part 1 J Psychosoc Nurs Ment Health Serv 49 11 2011 13 16
42. R.H. Howland A critical evaluation of the cardiac toxicity of citalopram: part 2 J Psychosoc Nurs Ment Health Serv 49 12 2011 13 16
43. K. Wenzel-Seifert, M. Wittmann, E. Haen QTc prolongation by psychotropic drugs and the risk of torsade de pointes Dtsch Ärztebl Int 108 2011 687 693